LOGIN  |  REGISTER
Terns Pharmaceuticals

Premier Health Announces the Appointment of Bruno Morel as its New CTO

April 08, 2024 | Last Trade: C$0.14 0.00 0.00

MONTRÉAL, April 08, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Health tech company, announces the appointment of Bruno Morel as the Corporation’s new Chief Technology Officer, effective immediately.

“We are very excited to have Bruno join Premier Health. His hiring follows our recent Canadian expansion and is one of the key catalysts of our technology roadmap. He will be an important member of the Corporation’s senior leadership team as we continue to expand and execute our growth strategy,” said Martin Legault, Chief Executive Officer.

Bruno has over 20 years of experience building complex software and managing development and operation teams in fast developing technology companies. Over the years, he has developed an expertise in the definition of technology strategies, the design of solutions as well as the delivery of large-scale projects. Bruno has held several roles including Chief Technology Officer, Vice President of Engineering, and Senior Director of Software and DevOps. His professional experience includes the development of custom applications in the health tech sector integrating AI and mobile applications for decentralized delivery of health services. Bruno is result oriented, a very good communicator and a natural leader, qualities that are crucial in the context of a fast-growing company. Bruno holds a Master of software architecture and application development from the École des technologies numérique avancées in Paris (ETNA).

"I'm very excited to join the company at this inflection point.” Said Bruno Morel “The health sector is in dire need of modernization and its entrance into the age of AI is starting now. My focus will be to ensure PHA’s leadership in that space."

Current Chief Technology Officer Éric Dupont, who joined Premier Health in December 2021, will continue with the Corporation for a transition period.

“Eric played an important role in our organisation over a critical geographical expansion period and his adaptation and communication skills enabled a smooth and efficient transition in that context.” said Martin Legault. “We wish him all the success with his new project.”

About Premier Health

Premier Health is a leading Canadian Healthtech company that provides a comprehensive range of outsourced services solutions for healthcare needs to governments, corporations, and individuals. Premier Health uses its proprietary LiPHe® platform to lead the healthcare services sector digital transformation to provide patients with faster, cheaper, and more accessible care services.

For Further Information Please Contact:

Mr. Jean-Robert Pronovost
Vice-President, Corporate Development
Premier Health of America Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it. / 1 800 231 9916

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This press release contains forward-looking information within the meaning of applicable securities legislation which reflects the current plans and expectations of the Corporation with respect to future events and financial performance. All statements other than statements of historical or current facts may be forward-looking information. Forward-looking information includes statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as ‘believes’, ‘continues’, ‘expects’, ‘projects’, ‘anticipates’, ‘plans’, ‘estimates’, ‘seeks’, ‘intends’, ‘targets’, ‘forecasts’, or negative or grammatical versions thereof and other similar expressions, or future or conditional verbs such as ‘may’, ‘will’, ‘should’, ‘would’ and ‘could’. Forward-looking information in this press release includes, but is not limited to, statements with respect to the execution of the Corporation’s growth strategy. Forward-looking information is based on management’s plans, estimates, projections, beliefs and opinions as at the date of this release, and the assumptions related to those plans, estimates, projections, beliefs and opinions may change; therefore, they are presented for the purpose of assisting the Corporation’s security holders in understanding management’s views at such time regarding those future outcomes and may not be appropriate for other purposes. Although the forward-looking information contained in this release is based on assumptions which the Corporation believes are reasonable, there can be no assurance that actual results will be consistent with such forward-looking information. The forward-looking information in this release relate only to events or information as of the date on which the statements are made and, except as specifically required by applicable securities laws, the Corporation undertakes no obligation to update or revise publicly any forward-looking information, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. There can be no assurance that the forward-looking information will prove to be accurate. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. The Corporation assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. These factors and others are more fully discussed in the filings of the Corporation with Canadian securities regulatory authorities available at www.sedarplus.ca

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB